TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11316161

Group type: EXPERIMENTAL
Intervention: 3 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 5 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Number of subjects: 154
Study: 15374128

Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin (2 mg per night)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8193492

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alfentanil 20 micrograms/kg plus suxamethonium 1.5 mg/kg
Number of subjects: 20
Study: 3788946

Group type: EXPERIMENTAL
Intervention: Commercial tracing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Missing migrant effect
Number of subjects: 0
Study: 11495176

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard cognitive-behavioral smoking cessation treatment (ST)
Number of subjects: 179
Study: 31016270

Group type: EXPERIMENTAL
Intervention: Upper extremity AVG-first access placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: AVF-first access placement
Number of subjects: 50
Study: 28634000

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 27461800

Group type: EXPERIMENTAL
Intervention: Polyethylene post
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glass post
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Composite post
Number of subjects: 16
Study: 24458754

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-exercise protein supplementation (PROT)
Number of subjects: 24
Study: 22692117

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐, protein‐, and ribose‐containing repletion drink (TEST; n = 15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbohydrates alone (CON; n = 17)
Number of subjects: 32
Study: 20412090

Group type: EXPERIMENTAL
Intervention: 20% arnica
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% vitamin K cream
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1% vitamin K and 0.3% retinol
Number of subjects: 100

Group type: COMPARATOR
Intervention: white petrolatum
Number of subjects: 100
Study: 17272735

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 16210859

Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 20 mg daily for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12014839

Group type: EXPERIMENTAL
Intervention: CoQ10 treatment in senescent rat hearts
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CoQ10 pre-incubation in human atrial tissue
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oral CoQ10 therapy for 2 weeks pre-operatively
Number of subjects: 3
Study: 11512194

Group type: EXPERIMENTAL
Intervention: Intensified smoking cessation program (inpatient program)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Outpatient smoking cessation program
Number of subjects: 89
Study: 7726101

Group type: EXPERIMENTAL
Intervention: Hearing protection devices (HPDs) - three insert HPDs and an earmuff under sound field condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Earmuff (used only in sound field condition)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 12
Study: 2343729

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.0, 2.0, and 3.0 MAC in 70% nitrous oxide)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Halothane (1.0, 2.0, and 3.0 MAC in 70% nitrous oxide)
Number of subjects: 4
Study: 7028921

Group type: EXPERIMENTAL
Intervention: Timolol (5 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30166260

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program (3 times weekly for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (maintaining routine activities)
Number of subjects: 50
Study: 28235533

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with fentanyl 2.5 μg/mL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine 0.0625% with fentanyl 2.5 μg/mL
Number of subjects: 90
Study: 25794237

Group type: EXPERIMENTAL
Intervention: Gum Chewing (GC)
Number of subjects: 30
Study: 24014447

Group type: EXPERIMENTAL
Intervention: Experimental conditions (stimulus condition)
Number of subjects: 74
Study: 23734436

Group type: EXPERIMENTAL
Intervention: Adequate sleep duration at night (ASDN) (>= 7 hrs)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Inadequate sleep duration at night (ISDN) (< 7 hrs)
Number of subjects: 332
Study: 19751085

Group type: EXPERIMENTAL
Intervention: Dyad condition (patient and SO received the intervention)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Solo condition (patient received the intervention)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 161
Study: 17295801

Group type: EXPERIMENTAL
Intervention: Food allergen-specific IgE/IgG4
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Egg white (DBPCFC +)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Wheat (DBPCFC +)
Number of subjects: 97

Group type: COMPARATOR
Intervention: DBPCFC for milk
Number of subjects: 97

Group type: COMPARATOR
Intervention: DBPCFC for egg white
Number of subjects: 97

Group type: COMPARATOR
Intervention: DBPCFC for soybean
Number of subjects: 97

Group type: COMPARATOR
Intervention: DBPCFC for wheat
Number of subjects: 97
Study: 15533804

Group type: EXPERIMENTAL
Intervention: 103Pd implantation with 90 Gy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 103Pd implantation with 115 Gy
Number of subjects: 161

Group type: COMPARATOR
Intervention: 44 Gy external beam radiation
Number of subjects: 161
Study: 12120181

Group type: EXPERIMENTAL
Intervention: Test and treat strategy for Helicobacter pylori
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test and scope strategy for Helicobacter pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eradication of H. pylori
Number of subjects: 0
Study: 9686702

Group type: EXPERIMENTAL
Intervention: Euphyllin Retard (theophylline)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7912581

Group type: EXPERIMENTAL
Intervention: Cell Saver used from the beginning of surgery (group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No blood conservation techniques (group 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cell Saver used in Redo patients (group 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cell Saver used in CABG patients (group 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cell Saver used in CABG and Redo patients (group 1)
Number of subjects: 112
Study: 2532034

Group type: EXPERIMENTAL
Intervention: Opaque fissure sealant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear fissure sealant
Number of subjects: 0
Study: 31120274

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention including a brief, 1-visit intervention on alcohol prevention in pregnancy
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1236
Study: 28128983

Group type: EXPERIMENTAL
Intervention: EPA-enriched liquid supplement (2 g/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Powdered supplement without EPA
Number of subjects: 53
Study: 25882965

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No regional anesthesia
Number of subjects: 93
Study: 23409890

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 0
Study: 21680143

Group type: EXPERIMENTAL
Intervention: Routine shunting
Number of subjects: 98

Group type: COMPARATOR
Intervention: Selective shunting when collateral perfusion pressure <40 mm Hg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cross-filling with normal to <70% contralateral carotid stenosis
Number of subjects: 98

Group type: COMPARATOR
Intervention: No cross-filling with <70% contralateral carotid stenosis
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cross-filling with ≥70% contralateral carotid stenosis
Number of subjects: 98

Group type: COMPARATOR
Intervention: No cross-filling with ≥70% contralateral carotid stenosis
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall comparison of cross-filling
Number of subjects: 98
Study: 18053000

Group type: EXPERIMENTAL
Intervention: Promotion of exclusive breastfeeding for the first 4-6 months of life according to WHO recommendations
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1721
Study: 16787192

Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Pentoxifylline-buflomedil association (Control)
Number of subjects: 123
Study: 15043177

Group type: EXPERIMENTAL
Intervention: Combination of a standard sliding-scale insulin regimen and routine diabetes medications
Number of subjects: 153

Group type: COMPARATOR
Intervention: Routine diabetes medications (control)
Number of subjects: 153
Study: 10890985

Group type: EXPERIMENTAL
Intervention: Medlite II frequency‐doubled Q‐switched Nd:YAG laser
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HGM K1 krypton laser
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DioLite 532‐nm diode‐pumped vanadate laser
Number of subjects: 27

Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 27
Study: 9279425

Group type: EXPERIMENTAL
Intervention: Treatment involving observation over a nine-week period, with three weeks of treatment focused on lexical development and verb constructions.
Number of subjects: 0
Study: 8362313

Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms/kg
Number of subjects: 60
Study: 3536528

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2C
Number of subjects: 42

Group type: COMPARATOR
Intervention: VMCP (vincristin, melphalan, cyclophosphamide and prednisolone)
Number of subjects: 42
Study: 29948858

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) on top of standard therapy for acute heart failure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 10
Study: 28359008

Group type: EXPERIMENTAL
Intervention: Hot water immersion (45°C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Icepacks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hot water immersion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hot water immersion and icepacks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Follow-up patients
Number of subjects: 42
Study: 25888477

Group type: EXPERIMENTAL
Intervention: £100 incentive payment
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Standard trial invitation letter
Number of subjects: 1015
Study: 23696211

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling and lavage (barbotage) combined with a US-guided corticosteroid injection in the subacromial bursa (group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Subacromial corticosteroid injection (SAI) alone (group 2)
Number of subjects: 48
Study: 21782095

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 26
Study: 18721166

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17469198

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH), 1 mg every second day for 6 months followed by alternating daily injections of 1 mg and 0.5 mg for another 6 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 12617373

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10958866

Group type: EXPERIMENTAL
Intervention: Total ejaculated spermatozoa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aged subjects
Number of subjects: 0
Study: 8965780

Group type: EXPERIMENTAL
Intervention: Sodium valproate added to the drug regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1738927

Group type: EXPERIMENTAL
Intervention: Enisoprost 50 micrograms p.o. q.i.d.
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Enisoprost 100 micrograms p.o. q.i.d.
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Enisoprost (both dosages)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Antibody-treated patients
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Patients not receiving antibody prophylaxis
Number of subjects: 374
Study: 6423328

Group type: EXPERIMENTAL
Intervention: mannitol 0.5 g/kg body weight
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 3887375

Group type: EXPERIMENTAL
Intervention: Protein-restricted group (0.4-0.6g/kg/BW)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study: 29584489

Group type: EXPERIMENTAL
Intervention: Rear-facing car safety seat (CSS) for infants <1 year
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Rear-facing car safety seat (CSS) for toddlers 12-17 months
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Forward-facing car seat with top tether
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Forward-facing car seat using lower anchors
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Booster seat use for children aged 4-7 years
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Vehicle seating position for children 12 years or younger
Number of subjects: 7725

Group type: EXPERIMENTAL
Intervention: Front seat position for children aged 8-12 years
Number of subjects: 7725
Study: 27913032

Group type: EXPERIMENTAL
Intervention: Fluticasone aerosol combined with theophylline tablets
Number of subjects: 44

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone aerosol combined with placebo tablets
Number of subjects: 44
Study: 24837666

Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) program
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1343
Study: 21924381

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including radio messages (23.1%), school fliers (20.1%), and friend referral (15%)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Team recruitment approach
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Case management strategies and make-up sessions
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Community field trips replacing structured sessions
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Overall intervention attendance rates
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 1-year and 2-year follow-ups
Number of subjects: 303
Study: 20064514

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Twice-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Number of subjects: 1023
Study: 18324377

Group type: EXPERIMENTAL
Intervention: Ultrasonic harmonic scalpel (UHS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional techniques (electrocautery and suture ligation)
Number of subjects: 104
Study: 16368146

Group type: EXPERIMENTAL
Intervention: Anecortave acetate 15 mg
Number of subjects: 530

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 530
Study: 15049299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11023461

Group type: EXPERIMENTAL
Intervention: saquinavir with ritonavir
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: delavirdine
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: delavirdine/adefovir
Number of subjects: 277

Group type: COMPARATOR
Intervention: adefovir
Number of subjects: 277
Study: 8725181

Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 200 mg/day
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 600 mg/day
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (Premarin, 0.625 mg/day)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 1580532

Group type: EXPERIMENTAL
Intervention: Yogurt (infant formula fermented with Lactobacillus bulgaricus and Streptococcus thermophilus)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Milk (infant formula)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 78
Study: 2857900

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active material (reintroduction of foods thought to provoke symptoms)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 31389035

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1)pdm09 isolates from the 2015-2016 season
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of influenza A(H1N1)pdm09 isolates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oseltamivir (Tamiflu) sensitivity
Number of subjects: 0
Study: 27354394

Group type: EXPERIMENTAL
Intervention: CBT-I Coach mobile application
Number of subjects: 18

Group type: COMPARATOR
Intervention: CBT-I (without app)
Number of subjects: 18
Study: 26663669

Group type: EXPERIMENTAL
Intervention: Nightly 50 mg sildenafil citrate
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 24642191

Group type: EXPERIMENTAL
Intervention: Oral oxycodone 5mg plus acetaminophen 325mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23019941

Group type: COMPARATOR
Intervention: Operation and post‐operative radiotherapy (Group A)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Operation, post‐operative radiotherapy, and QLR (Group B)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (Group C)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation and QLR (Group D)
Number of subjects: 156
Study: 20034617

Group type: EXPERIMENTAL
Intervention: attend-threat training
Number of subjects: 24

Group type: COMPARATOR
Intervention: avoid-threat training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: cognitive training
Number of subjects: 24
Study: 18164965

Group type: EXPERIMENTAL
Intervention: GG genotype of VEGF-1154 (A/G)
Number of subjects: 146
Study: 15951325

Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg kg(‐1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15071267

Group type: EXPERIMENTAL
Intervention: Active pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 0
Study: 10542981

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT) with head‐down tilt
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active cycle of breathing techniques (ACBT) without head‐down tilt
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT) in horizontal position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT)
Number of subjects: 19
Study: 9046850

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine at 10 ml/hr
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% lidocaine at 10 ml/hr
Number of subjects: 30
Study: 2058816

Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (0.5 mg terbutaline sulphate)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ventolin Rotahaler (0.4 mg salbutamol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6575836

Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus 5 doses of intrathecal methotrexate (i.t. MTX)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Intrathecal methotrexate plus dexamethasone (i.t. MTX-DMT)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus i.t. MTX-DMT
Number of subjects: 322

Group type: COMPARATOR
Intervention: Intrathecal methotrexate alone
Number of subjects: 322
Study: 30925957

Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 146
Study: 28747193

Group type: EXPERIMENTAL
Intervention: Training to improve recording of work ability illnesses and improved follow-up procedures in intervention units
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care in control units
Number of subjects: 22
Study: 25785701

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment breathing 100% oxygen under 2.5 ATA for 60 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxic group breathing room air under 1.2 ATA for 70 minutes
Number of subjects: 20
Study: 24351352

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone preoperatively
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (dexamethasone and placebo)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 64
Study: 21368716

Group type: EXPERIMENTAL
Intervention: GTS-21 (150 mg, orally three times per day for 3 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14